Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAPEO.L Regulatory News (APEO)

  • There is currently no data for APEO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues update on abrdn Private Equity Opportunities Trust (APEO): Resilient NAV and stable balance sheet

25 Oct 2023 11:34

Edison Investment Research Limited Edison issues update on abrdn Private Equity Opportunities Trust (APEO): Resilient NAV and stable balance sheet 25-Oct-2023 / 11:34 GMT/BST The issuer is solely responsible for the content of this announcement.


 

London, UK, 25 October 2023

 

Edison issues update on abrdn Private Equity Opportunities Trust (APEO): Resilient NAV and stable balance sheet

abrdn Private Equity Opportunities Trust (APEO) posted a 12-month NAV TR of 5.1% to end-September 2023 amid persistently muted exit activity across PE markets and FX headwinds from stronger sterling. APEO’s drawdowns continue to outpace distributions, but the 12-month net capital calls were more than offset by the proceeds APEO received from the partial sale of its co-investment in non-food discount retailer Action. As a result, APEO’s balance sheet headroom, as measured by its commitment coverage ratio, remained broadly stable versus end-2022. Its discount to NAV of 44% is wider than its 10-year average of 23% and the c 10% average discount for buyout portfolios traded in the secondary markets in H123.

APEO offers quality exposure to the PE mid-market through a portfolio of investments managed by carefully selected, top-tier European general partners (GPs) with solid sector expertise (the 12 ‘core’ GPs make up 55% of APEO’s NAV). This high-conviction strategy has proved successful over the mid to long term with APEO’s five- and 10-year NAV TR to end-September 2023 at c 15% pa, ahead of both the MSCI Europe Small Cap Index and the UK All-Share Index, and broadly in line with its close PE peers. Moreover, its combined 52% exposure to less cyclical sectors such as technology (typically profitable B2B software), healthcare and consumer staples, together with the wide discount to NAV, may offer some downside protection in the current environment.

Click here to view the full report.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first company in-market 17 years ago, Edison has more than 100 employees and covers every economic sector. Headquartered in London, Edison also has offices in New York, Sydney and Wellington.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Milosz Papst +44 (0)20 3077 5720 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1757273 25-Oct-2023 

corporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
9th Jun 20237:00 amRNSNotice of Results
17th May 202311:51 amRNSHolding(s) in Company
17th May 20237:00 amRNSEstimate NAV at 30 April 2023
25th Apr 202311:52 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSEstimated NAV at 31 March 2023
11th Apr 202311:23 amRNSQuarterly disclosure
22nd Mar 20231:41 pmRNSResult of AGM
16th Mar 20237:00 amRNSEstimated NAV at 28 February 2023
9th Mar 20237:00 amRNSFirst Interim Dividend
14th Feb 20237:00 amRNSEstimated NAV at 31 January 2023
10th Feb 20238:57 amRNSDoc re. Annual Financial Report
9th Feb 20234:40 pmRNSSecond Price Monitoring Extn
9th Feb 20234:35 pmRNSPrice Monitoring Extension
31st Jan 202311:38 amRNSDirector/PDMR Shareholding
31st Jan 202310:49 amRNSAnnual Financial Report
31st Jan 20237:00 amRNSAnnual Financial Report
18th Jan 20232:10 pmRNSNotice of Results
18th Jan 20237:00 amRNSEstimated NAV at 31 December 2022
9th Jan 20238:51 amRNSQuarterly disclosure
15th Dec 20227:00 amRNSEstimated NAV at 30 November 2022
13th Dec 20223:18 pmRNSFourth Interim Dividend Announcement
28th Nov 20227:01 amRNSCompany Secretary - Change of Name
21st Nov 20224:36 pmRNSPrice Monitoring Extension
14th Nov 20227:00 amRNSEstimated NAV at 31 October 2022
2nd Nov 20222:13 pmRNSDirector/PDMR Shareholding
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:36 pmRNSPrice Monitoring Extension
28th Oct 20229:42 amRNSEdison update on abrdn Private Equity Opp Trst
24th Oct 20224:41 pmRNSSecond Price Monitoring Extn
24th Oct 20224:36 pmRNSPrice Monitoring Extension
14th Oct 20227:00 amRNSEstimated NAV at 30 September 2022
10th Oct 20227:00 amRNSIncrease of Loan Facility
7th Oct 202210:33 amRNSQuarterly disclosure
16th Sep 20224:35 pmRNSPrice Monitoring Extension
15th Sep 20227:00 amRNSEstimated NAV at 31 August 2022
9th Sep 20224:36 pmRNSPrice Monitoring Extension
8th Sep 20224:36 pmRNSResearch from QuotedData
8th Sep 202211:21 amRNSDirector/PDMR Shareholding
8th Sep 202210:11 amRNSDirector/PDMR Shareholding
8th Sep 20227:00 amRNSThird Interim Dividend
12th Aug 20227:00 amRNSEstimated NAV at 31 July 2022
10th Aug 20225:49 pmRNSDirector/PDMR Shareholding
9th Aug 20227:00 amRNSEdison issues review on Abrdn Private Equity Opp.
21st Jul 20224:35 pmRNSPrice Monitoring Extension
14th Jul 202210:26 amRNSDoc re. Half Yearly Report
14th Jul 20227:00 amRNSEstimated NAV at 30 June 2022
5th Jul 20222:18 pmRNSQuarterly disclosure
30th Jun 20224:36 pmRNSPrice Monitoring Extension
30th Jun 20227:00 amRNSHalf-year Report
16th Jun 20227:00 amRNSEstimated NAV at 31 May 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.